eligibility_summary
MM (IMWG). Regimen A1: 1–3 prior lines incl PI+IMiD, A2: newly diagnosed, untreated. Regimen B: ≥1 prior incl PI+len and len‑refractory OR ≥2 prior incl PI+len. Regimens C–E: newly diagnosed, untreated. Weight ≥40 kg, ECOG 0–2, measurable disease. Exclude: serious infection/autoimmune/cardiac, recent therapies (washouts apply), allo SCT <6 mo, auto ≤12 wks, unresolved tox >G1, prior CD3‑redirector, O2‑dependent lung dz, HIV, active HBV/HCV, stroke/seizure <6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1b, multiple myeloma. Interventions: 1) JNJ-79635322 (ramantamig) — subcutaneous T-cell–engaging trispecific antibody that binds BCMA and GPRC5D on myeloma cells and CD3 on T cells, redirecting T-cell cytotoxicity. 2) Daratumumab — subcutaneous anti-CD38 IgG1 monoclonal antibody inducing ADCC/CDC and apoptosis, and depleting CD38+ immunosuppressive cells. 3) Lenalidomide — oral immunomodulatory drug (IMiD), a cereblon E3 ligase modulator causing IKZF1/3 degradation, enhancing T/NK cell activity and direct anti-myeloma effects. 4) Pomalidomide — oral IMiD with similar cereblon-mediated mechanism. Targets/pathways: malignant plasma cells expressing BCMA, GPRC5D, and CD38, T-cell activation via CD3, cereblon-IKZF pathway, ADCC/CDC, tumor immune microenvironment. Combinations: JNJ-79635322 + daratumumab ± lenalidomide, or JNJ-79635322 + pomalidomide.